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Chimeric antigen receptor (CAR) T cell efficacy against solid tumors is currently
limited by several immune escape mechanisms, which may include tumor-derived
extracellular vesicles. Advanced neuroblastoma is an aggressive childhood tumor
without curative treatment options for most relapsed patients today. We here evaluated
the role of tumor-derived extracellular vesicles on the efficacy of CAR T cells
targeting the neuroblastoma-specific antigen, CD171. For this purpose, CAR T cell
activation, cytokine production, exhaustion, and tumor cell-directed cytotoxicity upon
co-culture was evaluated. Tumor-derived extracellular vesicles isolated from SH-SY5Y
neuroblastoma cells neither affected CAR T cell activation nor expression of inhibitory
markers. Importantly, exposure of CD4+ CD171-specific CAR T cells to tumor-derived
extracellular vesicles significantly impaired tumor cytotoxicity of CAR T cells. This effect
was independent of neurotrophic receptor tyrosine kinases 1 or 2 (NTRK1, NTRK2)
expression, which is known to impact immune responses against neuroblastoma. Our
results demonstrate for the first time the impact of tumor-derived extracellular vesicles
and non-cell-mediated tumor-suppressive effects on CD4+ CAR T cell efficacy in a
preclinical setting. We conclude that these factors should be considered for any CAR
T cell-based therapy to make CAR T cell therapy successful against solid tumors.
Keywords: immunotherapy, pediatric oncology, neuroblastoma, solid tumors, neurotrophic receptor tyrosine
kinase
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INTRODUCTION
Solid tumor therapy is faced with multiple obstacles that
complicate efficient reduction, and ultimately, elimination of
cancer cells. Immune surveillance and reinforcement of immune
cell activity as a therapeutic option has become increasingly
successful. The introduction of checkpoint inhibitors into clinical
practice and the advent of cellular immunotherapy, such as
CAR T cell-based therapy, holds great promise. Redirection
of autologous T cells to a specific tumor-associated antigen
via a transfected chimeric antigen receptor (CAR) creates
augmented target specificity and improved T cell cytotoxicity.
To date, the success of CAR T cell therapy has mostly
been limited to the treatment of hematopoietic cancers (1–
5). CAR T cell therapy for solid tumors can be hampered
by an anti-inflammatory tumor microenvironment, which
promotes immune escape mechanisms (6, 7). Here, intercellular
communication plays a crucial role in establishing a pro-
tumorigenic micromilieu that facilitates cancer spread and
immune cell exclusion or dormancy (8). It is increasingly clear
that communication between cells can be mediated over distant
sites by secretion and uptake of extracellular vesicles, which
carry multiple biologically active proteins on their surfaces and
generally reflect the molecular composition of their parent cells.
Tumor-derived extracellular vesicles (TEVs) are enriched in
immunoregulatory proteins including FasL, PD-L1, inhibitory
cytokines, classical, and non-classical MHC molecules and
the corresponding tumor-associated antigens (9–12). PD-L1
on tumor exosomes is especially relevant in settings where
patients are treated with antibodies against this checkpoint
inhibitor. Importantly, exosomal PD-L1 levels correlated with
response to therapy and suppression of exosomal PD-L1-induced
systemic anti-tumor immunity (13, 14). These findings suggest
that exosomal composition can massively impact immune cell-
directed therapies.
Neuroblastoma, the most-common pediatric extracranial
solid tumor, derives from neural precursor cells and displays
a high biological as well as clinical heterogeneity (15, 16).
Neuroblastoma ranges from disease that can spontaneously
regress to high-risk cases for which patient survival is
below 40% regardless of current standard multimodal therapy
consisting of surgery, polychemotherapy, and radiation (15).
Influential factors that can be of prognostic value are e.g.,
oncogene amplification, ploidy, allelic loss, and tumor stage.
Furthermore, mutually exclusive expression of the neurotrophic
receptor tyrosine kinases 1 or 2 (NTRK1, NTRK2) has
prognostic significance, and both kinases contribute to distinct
neuroblastoma biologies, in particular to differences in tumor
immunogenicity (17). NTRK1 expression in neuroblastoma
has been reported to be correlated with low tumor stage,
enhanced DNA repair, a retention of immunogenicity associated
with higher degree of leukocyte infiltration, a higher degree
of differentiation, higher chemotherapeutic sensitivity, and
an inhibitory effect on angiogenesis. All of these features
conceivably contribute to excellent patient survival when tumors
express NTRK1 (18–22). In contrast, NTRK2 expression in
neuroblastoma has been reported to be associated with MYCN
amplification, enhanced migratory properties leading to early
metastases and a resistance to first-line chemotherapeutics, all of
which contribute to poor patient survival (20, 22–24).
Previously, we preclinically evaluated CAR T cells targeting
the CE7 epitope of the CD171 tumor-associated antigen in
neuroblastoma models for their therapeutic efficacy as well
as toxicity and safety (25, 26). CD171-directed CAR T cells
are currently being tested in a phase I trial for patients
with recurrent or refractory neuroblastoma (ClinicalTrials.gov
Identifier: NCT02311621). Here we investigate the potential
influence of TEVs on the efficacy of CD171-specific CAR
T cells from CD4+ and CD8+ T cell subsets in preclinical
neuroblastoma models and assess a potential differential
involvement of neurotrophin receptors in this process.
MATERIALS AND METHODS
Cell Culture
SH-SY5Y parental cells were maintained in RPMI Medium
(Gibco) supplied with 10% fetal calf serum (FCS). Stable
expression of NTRK1 or NTRK2 in SH-SY5Y human
neuroblastoma cells was achieved as described before (27).
SH-SY5Y-NTRK1 and SH-SY5Y-NTRK2 were cultivated in
RPMI medium, supplied with 10% FCS and 500µg/ml G418
(Sigma). All cell lines underwent Short Tandem Repeat DNA
genotyping for cell line identification as well as weekly testing
for mycoplasma using the PlasmoTestTM Kit (Invitrogen). The
general number of passages between thawing and use was <20
for all experiments performed.
Isolation of Extracellular Vesicles
To obtain extracellular vesicles released from SH-SY5Y, SH-
SY5Y-NTRK1, and SH-SY5Y-NTRK2 cells, cells were cultured
for 9 h in RPMI medium supplemented with 10% extracellular
vesicle-depleted fetal bovine serum (FCS), 5% penicillin-
streptomycin (Pen Strep, 10,000 U/mL, Life Technologies), and
1% L-glutamine (L-Glutamine, 200mM, Life Technologies).
Conditionedmedia was subjected to ultracentrifugation at 10,000
× g in a fixed angle Type 45 Ti rotor (Beckman Coulter)
for 30min in order to remove membrane patches, followed by
a further ultracentrifugation step at 120,000 × g for 120min
at 4◦C using a swinging bucket SW 40 Ti rotor (Beckman
Coulter). Pelleted TEVs were resuspended in 0.9% NaCl and
stored at −20◦C until usage. The obtained TEV fractions
were characterized by (i) SDS-PAGE and western blotting to
verify typical extracellular vesicle marker expression (CD81,
TSG101, syntenin) and the absence of intracellular proteins
or endosomes (calnexin) according to consensus requirements
defining extracellular vesicles (28), (ii) nano-particle tracking
analysis using ZetaView analyses (Particle Metrix, Diessen,
Germany) to define size and particle concentration (29) and (iii)
protein assay (Thermo Scientific, Darmstadt, Germany) to define
protein concentration.
CAR Constructs
The CD171-specific CE7-CAR was cloned into the SIN epHIV7
lentiviral vector, and lentivirus was propagated in 293T cells
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(30, 31). The scFv was codon-optimized and subsequently linked
to a 229-amino acid spacer domain from the human IgG4
hinge. The spacer domain was modified by two substitutions,
L235D and N297Q, to reduce binding to the IgG Fc gamma
receptor (32). The spacer domain connects the antigen-binding
domain to the CD28 transmembrane domain, which is followed
by the signaling module containing the CD3zeta cytoplasmic
domain and 4-1BB. The CAR construct also contained a
T2A self-cleaving peptide and truncated epidermal growth
factor receptor (EGFRt) allowing for CAR T cell detection
and enrichment.
Generation and Cultivation of
CD171-Specific CAR T Cells
Apheresis products were obtained from healthy donors (Charité
ethics committee approval EA2/216/18) and peripheral blood
mononuclear cells were isolated using Ficoll-Paque (GE
Healthcare). CD4+ and CD8+ T cells were obtained by positive
selection using immunomagnetic microbeads (Miltenyi Biotec),
and activated with anti-CD3/CD28 beads (Life Technologies).
On day three, activated T cells were transduced with the CAR-
containing lentivirus. EGFRt+ CAR T cells were enriched by
immunomagnetic selection with biotin-conjugated cetuximab
(Bristol-Myers Squibb) and streptavidin microbeads (Miltenyi
Biotec). Untransduced T cells were used as negative controls
alongside CAR T cells in all experiments. CAR T cells and control
T cells were cryopreserved until further use. Cryopreserved cells
were thawed, stimulated with irradiated peripheral blood
mononuclear cells, irradiated lymphoblastoid TMLCL cells, and
OKT3 (30 ng/mL, Miltenyi Biotec), and expanded according to
a rapid expansion protocol (26). CD4+ T cells were supplied
with IL2 (50 U/µl) and IL7 (10 ng/µl) and CD8+ T cells were
supplied with IL2 (50 U/µl) and IL15 (10 ng/µl) every other day
following expansion. Functional in vitro assays were conducted
between days 11 and 16 of culture.
PCR
DNA was isolated from SH-SY5Y parental cells and the
stable expressing SH-SY5Y-NTRK1 and SH-SY5Y-NTRK2 cell
models using the Nucleospin Tissue Kit (Macherey-Nagel).
PCR-based detection of neurotrophin receptor expression was
achieved by PCR-based amplification using primers for NTRK1
(forward: ACCATGCTGCCCATTCGCTG, reverse: GAGGGC
AGGCCCCAGTATTC) or NTRK2 (forward: GCAATGATG
ATGACTCTGCC, reverse: GGAACACTTTTCCAAAGGCT),
and subsequent separation of PCR products in 1% agarose gels
by electrophoresis.
Western Blotting
Tumor cells were detached by trypsin, washed twice with PBS
and lysed in RIPA buffer including protease inhibitors and the
Phosphatase Inhibitor Cocktail (Roche). Proteins were separated
by SDS-PAGE before western blotting with pan-Trk (C-14; sc-
11, Santa Cruz Biotechnology) and phospho-Trk (#4621, Cell
Signaling Technology) antibodies.
Flow Cytometry
Cell-surface expression of CD4 (BD Biosciences), CD8
(BioLegend), and CD171 (cat#130-100-691, Miltenyi Biotec)
was detected by fluorophore-conjugated monoclonal antibodies.
EGFRt expression was detected using biotinylated cetuximab
(Bristol-Myers Squibb) and a phycoerythrin (PE)-conjugated
streptavidin antibody (BioLegend). T cell activation and
exhaustion were assessed by fluorophore-conjugated monoclonal
antibodies detecting CD137 (BioLegend), CD25 (BioLegend),
PD-1 (also known as PDCD1 or CD279, BioLegend), TIM3
(Biolegend), and LAG3 (BD Biosciences). Flow cytometry was
performed on a Fortessa X-20 (BD Biosciences) and data were
processed using FlowJo software (Tree Star Inc.). Dead cells were
excluded from analyses using LIVE/DEADTM Fixable Green
Dead Cell Stain Kit (Life Technologies).
TEV Co-culture and Exposure
T cells (2 × 105) were co-cultured with 10 µg TEV protein per
well in 96-well flat-bottom plates in triplicate for 24 h in RPMI
supplemented with 10% extracellular vesicle-depleted FCS. After
24 h cells were pooled, washed twice with PBS and either used
in FACS analyses or for viability assessment using trypan blue.
T cells were then mixed with tumor cells at an effector:target
ratio of 1:2. T cells primed with TEVs derived from parental
SH-SY5Y cells were co-cultured with SH-SY5Y target cells. T
cells primed with TEVs derived from SH-SY5Y-NTRK1 or SH-
SY5Y-NTRK2 cells were co-cultured with SH-SY5Y-NTRK1 or
SH-SY5Y-NTRK2 target cells, respectively. Viability, activation
and exhaustion were assessed in CAR T cells after 24 h using
FACS-based detection of cell surface markers.
Functional Assays
For cytokine release assays, 2 × 105 T cells were seeded together
with stimulator cells at a 1:2 effector:target ratio. After 24 h,
conditioned media was collected and stored at −80◦C until
analysis of IL2 and IFNG using the OptEIATM ELISA (BD
Biosciences) according to the manufacturer’s instructions. CAR
T cell-induced cytotoxicity was quantified in a biophotonic
luciferase assay in which the neuroblastoma cells stably
transduced with the GFP-ffLuc_epHIV7 reporter plasmid served
as tumor target cells. Target cells were co-cultured with negative
control or CAR T cells. The maximal biophotonic luciferase
signal was obtained by measuring luminescence of target cells
in the absence of CAR T cells (RLUmax, maximal relative light
unit). After 24 or 72 h, 0.14mg D-luciferin (PerkinElmer Inc.)/ml
medium was added to each well, and the biophotonic signal
was detected. Lysis was determined as [1-(RLUsample/RLUmax)]
× 100 in relation to untreated cells. For sequential treatment, the
additive amount of tumor lysis was calculated related to viable
tumor cells at day 3. If not indicated otherwise, all data points
were obtained as technical triplicates.
Statistical Analysis
The differences between treatment groups were statistically
analyzed using unpaired Student t tests in PRISM (GraphPad
Software, Inc., San Diego, CA, USA). P < 0.05 were considered
statistically significant.
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FIGURE 1 | Characterization of extracellular vesicles preparations derived from SH-SY5Y and SH-SY5Y-NTRK cells by Nanotracking analysis and immunoblotting.
(A) The mean TEV size did not vary among the different TEV preparations (n = 9). (B) Immunoblotting of TEV preparation and cell lysates for typical TEV markers
TSG101, Syntenin, and CD81. Calnexin as protein of endoplasmic reticulum served as negative control. (C) CD4+ and CD8+ T cell viability after 24 h co-culture with
10 µg extracellular vesicles, accessed via flow cytometry after live-dead staining. Depicted is mean of three independent experiments with each using technical
triplicates with error bars representing standard deviation (SD).
RESULTS
Neuroblastoma TEVs Do Not Impair CAR T
Cell Viability
Since TEVs have been reported to modify immune effector
functions (33, 34), we investigated the impact of extracellular
vesicles derived from the human SH-SY5Y neuroblastoma
cell line, which is lacking neurotrophin receptor expression,
or neurotrophin-expressing models on CAR T cell efficacy.
Models stably expressing each neurotrophin receptor were used
to explore the impact of neurotrophin receptor expression
on TEVs and CD171-targeting CAR T cell efficacy in vitro.
Ectopic NTRK1 and NTRK2 expression in SH-SY5Y cell
models (referred to hereafter as SH-SY5Y-NTRK1 and SH-
SY5Y-NTRK2, respectively) was validated using RT-PCR and
western blotting. Constitutive activation was verified for both
receptors as previously reported (Supplementary Figure 1) (35).
TEVs were isolated from medium conditioned by SH-SY5Y, SH-
SY5Y-NTRK1, or SH-SY5Y-NTRK2 cells. Nanoparticle tracking-
based characterization of the TEV preparation revealed that
vesicle diameter ranged between 120 and 150 nm, which
is typical for extracellular vesicles (for further details see
Supplementary Table 1). The CD81 tetraspanin protein and
the syntenin and TSG101 cytosolic proteins, which are either
ESCRT complex-associated proteins or linked to vesicle release,
were detected in all extracellular vesicles preparations, but the
intracellular protein, calnexin, was not (Figures 1A,B). This
marker profile confirmed TEV preparation purity, and excluded
contamination with cellular debris. To investigate the impact of
extracellular vesicles derived from SH-SY5Y parental or NTRK-
expressing cells on CAR T cell viability, we co-incubated CAR
T cells with 10 µg TEV, then subsequently assessed viability.
Viability of CD4+ or CD8+ CAR T or control T cells was
not significantly altered by 24 h of co-culture with extracellular
vesicles derived from SH-SY5Y parental or NTRK-expressing
cells (Figure 1C).
TEV Priming Impairs CD4+ CAR T Cell
Cytotoxicity, While CD8+ CAR T Cell
Activity Is Unaffected
Next, we explored whether TEVs could influence CAR T cell
efficacy. CAR T cells were exposed to TEVs for 24 h before
co-incubation with tumor cells and assessment of cytotoxicity
(Figure 2A). For this purpose, SH-SY5Y, SH-SY5Y-NTRK1,
and SH-SY5Y-NTRK2 cells were transduced with a GFP-
firefly luciferase reporter plasmid to facilitate viable tumor
cell quantification. Cytotoxicity was assessed following 24 h of
co-culture measuring residual luminescence signals of viable
tumor cells. TEV priming of CD4+ CAR or control T cells
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FIGURE 2 | TEV-priming results in impaired CD4+ CAR T cell cytotoxicity. (A) Illustration of co-culture experiments with prior TEV-priming of CAR T cells. Co-culture
experiments were conducted in three independent experiments with technical triplicates each. (B) Cytotoxicity assay of TEV-primed and unprimed CAR T cells
measured biophotonically after co-incubation with GFP-ffluc expressing NTRK1 or NTRK2 expressing SH-SY5Y cell lines for 24 h at an effector:target ratio of 1:2.
Co-culture experiments were conducted in three independent experiments with technical triplicates each. (C) Concentration of IL2 and (D) IFNG from supernatant of
co-culture of TEV-primed and unprimed CAR T cells with tumor cells at an effector:target ratio of 1:2 quantified by ELISA. Cytokine measurements were conducted in
three independent experiments with technical triplicates each. All experiments are depicted with error bars representing SD. *p < 0.05; **p < 0.01.
significantly impaired the killing activity of these cells, regardless
of neurotrophin receptor expression in the SH-SY5Y target cells,
whereas the TEV priming of CD8+ CAR or control T cells did
not affect neuroblastoma cell cytotoxicity (Figure 2B). Control
T cells demonstrated a comparably low degree of cytotoxicity,
most likely due to alloreactivity. Co-culturing TEV-primed
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FIGURE 3 | SH-SY5Y-NTRK1 increases CD171 expression in tumor cell lines and leads to improved CAR T cell cytotoxicity that is not significantly dictated through
CD171 expression on the target tumor cell line. (A) Mean CD171 surface expression intensity (MFI) on SH-SY5Y-NTRK1, SH-SY5Y-NTRK2, and parental control by
(Continued)
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FIGURE 3 | flow-cytometric analysis. Assessment of CD171 surface expression was done in three independent experiments. Expressed in mean with error bars
representing SD. (B) Luciferase-based cytotoxicity assay of CD171-specific CAR T cells from CD4+ or CD8+ subsets against GFP-ffluc expressing SH-SY5Y-NTRK1,
-NTRK2 and parental control measured after 24 and 72 h in an effector:target ratio of 2:1 and (C) 1:2. (D) Luciferase-based cytotoxicity assay of CD171-specific CAR
T cells from CD4+ or CD8+ subsets against CD171-high SH-SY5Y-NTRK2 measured after 24 and 72 h in an effector:target ratio of 2:1 and (E) 1:2. Cytotoxicity
assays were conducted in four independent experiments with technical triplicates each and expressed in mean with error bars representing SD. *p < 0.05; **p < 0.01.
CD171-specific CD4+ or CD8+ CAR T cells with SH-SY5Y or
SH-SY5Y-NTRK cells consistently reduced the release of IL2
or IFNG by either CAR T cell type compared to unprimed
T cells, although comparisons only reached significance for
the CD4+ CAR T cells co-incubated with SH-SY5Y-NTRK2
cells (Figures 2C,D). FACS analyses revealed no differences in
expression of activation markers or inhibitory receptors on
primed vs. unprimed CD171-specific CD4+ and CD8+ CAR T
cells after tumor cell co-culture (Supplementary Figures 2A,B).
Our data demonstrate that TEV priming reduces CD171-specific
CD4+ CAR T cell efficacy, but does not affect CD8+ CAR T
cell-mediated cytotoxicity.
NTRK1 Expression Augments CAR T Cell
Cytotoxicity
Since neurotrophin receptor expression on neuroblastoma cells
is known to have an effect on immune cells, we investigated
whether NTRK1 or NTRK2 expression influences CAR T cell
efficacy. We first determined CD171 expression in SH-SY5Y
and SH-SY5Y-NTRK cells using flow cytometry. Interestingly,
CD171 expression was modulated by NTRK receptor expression
(Figure 3A), and was highest in NTRK1-expressing SH-SY5Y
cells. We next examined whether the level of target-antigen
expression on tumor cells altered CAR T cell function. CD171-
specific CAR T cells were co-cultured with neuroblastoma
reporter cells at an effector:target ratio of 2:1 or 1:2, respectively.
Cytotoxicity was assessed following 24 and 72 h of co-culture
measuring residual luminescence signals of viable tumor cells.
At an effector:target ratio of 2:1, neuroblastoma cell killing
was significantly more effective in the presence of CD4+ and
CD8+ CD171-specific CAR T compared to control T cells
(Figure 3B). After 24 h, CD4+ CAR T cell-directed SH-SY5Y-
NTRK1 cytotoxicity was significantly higher than cytotoxicity
to SH-SY5Y control cells (p = 0.023) or SH-SY5Y-NTRK2
cells (p = 0.0005). CD8+ CAR T cells mediated cytotoxicity
even more strongly compared to CD4+ CAR T cells, and
killing efficacy was significantly higher toward SH-SY5Y-NTRK1
compared to parental control cells (p = 0.005) or SH-SY5Y-
NTRK2 cells (p = 0.0005, mean 94% vs. 84.2% vs. 74.9%
after 24 h). These differences in killing efficacy were more
prominent at effector:target ratios of 1:2. In contrast, control
T cells displayed moderate or no cytotoxicity at effector:target
ratios of 2:1 and 1:2, respectively (Figures 3B,C). In order to
assess whether cytotoxicity induced by CD171-specific CAR
T cells depended on antigen expression levels, we engineered
SH-SY5Y-NTRK2 cells, which express only low CD171 levels,
to over-express CD171 (Supplementary Figure 3). Cytotoxicity
of CD4+ CAR T cells (effector:target ratio of 2:1) was not
significantly affected by CD171 expression on SH-SY5Y-NTRK2
cells after 24 h (mean 42.8% vs. 38.4%) or 72 h (mean 68.4%
vs. 64%, Figure 3D). Control T cells displayed little or no
cytotoxicity against target cells, regardless of CD171 expression
level. CD8+ CAR T cells displayed higher cytotoxicity against
both cell lines when compared to CD4+ CAR T cells, reaching a
maximum killing efficiency at an effector:target ratio of 2:1 when
CD171 expression was high. At lower effector:target ratios (1:2),
tumor cell killing was decreased regardless of CD171 expression
levels in SH-SY5Y-NTRK2 cells (Figure 3E). Again, we observed
comparably low and unspecific alloreactive cytotoxicity of the
control T cells. These experiments demonstrate that differential
NTRK expression on neuroblastoma cells alters CD171-directed
CAR T cell cytotoxicity, and that this effect is independent of
endogenous CD171 expression levels on target cells.
NTRK1 Induces Elevated Expression of
Activation Markers in CAR T Cells
NTRK-induced modulation of CAR T cell cytotoxicity was
further analyzed using in vitro assays. Cytokine release (IL2 and
IFNG) from CAR T cells following co-culture with SH-SY5Y,
SH-SY5Y-NTRK1, and SH-SY5Y-NTRK2 cells was quantified
by ELISA. Co-incubation with either the parental SH-SY5Y
cell line or cell models expressing a neurotrophin receptor
induced IL2 and IFNG release from CD171-specific CAR-T
cells, but not control T cells (Figure 4A). Activation markers
(CD25 and CD137) on CD4+ and CD8+ T cells harboring
the CD171-specific CAR were induced when co-cultivated with
SH-SY5Y cells, and this activation was independent of NTRK
receptor expression (Figure 4B). CD25 upregulation on CD4+
and CD8+ CAR T cells was significantly more pronounced
in the presence of SH-SY5Y-NTRK1 compared to parental
control cells. Co-cultivation with either SH-SY5Y-NTRK1 or SH-
SY5Y-NTRK2 (compared to parental control cells) significantly
increased CD137 expression on CD8+ CAR T cells. In contrast,
co-incubation with different neuroblastoma cells yielded mixed
results on the expression of PD-1, TIM3 and LAG3 inhibitory
receptors on CAR T cells. While TIM3 expression was
significantly induced by exposure to either SH-SY5Y cells or the
NTRK-expressing models, PD-1 expression on CD171-directed
CAR T cells remained low in all co-culturing conditions analyzed
(Figure 4C). Induction of LAG3 expression was restricted to
CD8+ CD171-directed CAR T cells, independent of NTRK
expression on target cells. Potential shifts in the distribution of
the inhibitory receptor repertoire on CAR T cell subpopulations
after exposure to SH-SY5Y cells and the NTRK-expressing
derivates were investigated using pie charts visualizing the degree
of inhibitory receptor expression in CAR T (Figure 4D) and
control T cells (Supplementary Figure 4).While relative changes
in CD4+ and CD8+ CART cell subpopulations expressing single,
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FIGURE 4 | SH-SY5Y-NTRK1 expression results in increased CAR T cell activity, whereas NTRK has no significant influence on cytokine production and expression of
exhaustion markers in CAR T cells. (A) Concentration of cytokines IL2 and IFNG in supernatant of CAR T cell and tumor in an effector:target ratio of 1:2 after 24 h
(Continued)
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FIGURE 4 | co-culture determined by sandwich ELISA. Flow cytometric analysis of T cell surface activation markers CD25 and CD137 on CAR and control T cells
after 24 h tumor co-culture. Depicted are double positive CAR and control T cells for CD4+ or CD8+ and CD25 or CD137. Cells were gated from living single cells. (B)
Flow cytometric analysis of surface activation markers: Proportion of CD25 and CD137 on CAR T cells after tumor co-culture for 24 h in an effector:target ratio of 1:1
are shown. Depicted are double-positive cells for CD4+ or CD8+ and CD25 or CD137. Cells were gated from living single cells. Flow cytometric analysis was
conducted in three independent experiments. (C) Flow cytometric analysis of surface exhaustion markers: Proportion of TIM3, PD-1, and LAG3 on CAR T cells after
tumor co-culture for 24 h in an effector:target ratio of 1:1. Depicted are double-positive cells for CD4+ or CD8+ and TIM3, PD-1, or LAG3. Cells were gated from living
single cells. Flow cytometric analysis was conducted in three independent experiments. (D) Distribution of no, single (+), double (++), or triple (+++) expression of
exhaustion markers on CD4+ and CD8+ CAR T cells after 24 h tumor co-culture in an effector:target ratio of 1:1. Single positivity (+) was defined as the sum of
TIM3+/PD-1−/LAG3−, TIM3−/PD-1+/LAG3− populations and TIM3−/PD-1−/LAG3+ populations. Double positivity (++) was defined as the sum of
TIM3+/PD-1−/LAG3+ populations, TIM3+/PD-1+/LAG3− populations and TIM3−/PD-1+/LAG3+ populations. Triple positivity (+++) was defined as
TIM3+/PD-1+/LAG3+ populations. Negative expression was defined as TIM3−/PD-1−/LAG3− populations. Bars showed mean values with error bars representing
SD. *p < 0.05; **p < 0.01.
double or all three inhibitory receptors were highest after co-
culture with SH-SY5Y-NTRK1 and lowest after co-culture with
the parental cell control, these effects did not reach statistical
significance. Our results demonstrate that co-cultivation with
SH-SY5Y cells induced cytokine release, up-regulated different
activation markers as well as the inhibitory LAG3 and TIM3
markers, but not PD-1, on CD171-specific CAR T cells.
DISCUSSION
Cell-based immunotherapies such as CAR T cells are now
entering clinical testing for solid tumor treatment. Although
the mechanism of action has been thoroughly investigated
in childhood tumors including neuroblastoma (26, 36), little
is known about host factors that could potentially modify
therapeutic efficacy. TEVs have repeatedly shown to be key
players in solid tumor formation and maintenance as well as
immunosurveillance (13, 14). Here we analyzed the interplay
between extracellular vesicles from preclinical neuroblastoma
models with differential expression of the master regulators,
NTRK1 and NTRK2, and CAR T cells, in order to identify
molecular factors that can be investigated and maybe even
manipulated to improve response to CAR T cell therapy. While
CAR T cell viability, expression of activation and exhaustion
markers as well as their cytokine production was largely
unaffected, CD4+ CAR T cell cytotoxicity was significantly
reduced in the presence of neuroblastoma-derived extracellular
vesicles independent of NTRK1/2 expression. These results
are in line with previous reports highlighting CD4+ T cell
sensitivity toward exosomes and their suppressive potential (37,
38). However, we did not observe decreased T cell viability in
the presence of TEVs that was described for TEVs derived from
other tumor types (37, 39). Taken together these results suggest
that suppressive effects of TEVs on T cell viability could vary
depending on the tumor entity from which they are derived and
on different CAR T cell subsets.
Even though NTRK1 and NTRK2 share extensive sequence
similarity and similar proximal signaling targets, their expression
is correlated with divergent effects on neuroblastoma biology
and malignancy (27, 35). NTRK1 and NTRK2 expression
are indicative of excellent and poor clinical outcome in
neuroblastoma, respectively, yet there is no data on the role
of NTRKs in cell-cell communication mediated by extracellular
vesicles. We show that expression of the NTRK1 neurotrophin
receptor in neuroblastoma cells augmented CAR T cell
cytotoxicity and activation compared to cells not expressing
NTRK1. In contrast, NTRK2 expression did not affect CAR T
cell cytotoxicity. This effect could not be attributed to altered
CAR T cell cytokine production, which was similarly induced
upon co-incubation with tumor cells, irrespective of NTRK1
expression. These results are in line with previously published
reports that NTRK1 expression on neuroblastoma cells enhanced
proliferation, activation and IFNG production in healthy donor
T cells (21, 27). These and other mechanisms, including MHC
class I re-expression in neuroblastoma cells stably transfected
to express NTRK1 and upregulation of immune modulating
genes by NTRK1, corroborate the idea that excellent prognosis
in patients with NTRK1-expressing neuroblastomas could be
attributed at least in part through pro-immunogenic features
mediated by NTRK1 (21).
It has been reported that TEVs reprogram CD8+ T cells
to become suppressor cells inhibiting proliferation of other T
cells (40). TEVs also inhibit T cell proliferation and cytolytic
activity in effector T cells and other effector immune cells such
as natural killer cells, and promote regulatory T cell proliferation
and formation of myeloid-derived suppressor cells through their
immunosuppressive cargo (9, 40–42). Of note, cytotoxic activity
of CD171-specific CAR T cells was independent of NTRK2
expression, which is a marker of aggressive neuroblastoma.
It remains to be elucidated whether NTRK2 inhibition by
small molecules, which is highly effective against preclinical
neuroblastoma models (23, 43), would further improve CAR T
cell therapy against NTRK2-expressing neuroblastomas. Single
agent-targeting of NTRK2, such as larotrectinib for NTRK2-
rearranged tumors in adults and children (44), has now been
approved for clinical application. Since TEVs, regardless of their
derivation from NTRK1- or NTRK2-expressing cells, display
obstructing effects on CD4+ CAR T cells in vitro, it should
be tested whether CD8+ CAR T cells are a better suited
for cell-based neuroblastoma immunotherapy. Vice versa, Tang
et al. showed that CAR T cell-derived extracellular vesicles
had potent anti-tumor properties and preserved their tumor-
targeting specificity (45). Thus, it is likely that the interplay
of tumor-derived and CAR T cell-derived extracellular vesicles
reprograms the tumor microenvironment and needs to be
considered when optimizing CAR T cell therapy for solid tumors.
A limitation of this study is the use of only one cell line.
Nevertheless, the neuroblastoma cell line SH-SY5Y ± NTRK1/2
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expression is a well-accepted and commonly used model for
neuroblastoma allowing in-depth analysis.
Here we demonstrate that CD171-specific CAR T cells are
functional and cytotoxic in preclinical models of neuroblastoma
with different neurotrophin receptor expression, thus, covering
a wide range of neuroblastoma biology. NTRK1-expressing
neuroblastoma cells were most susceptible to both CD4+ and
CD8+ CAR T cell-mediated killing, while NTRK2-expressing
cells were significantly more resistant. TEVs abrogated the
effect of CD4+, but not CD8+, CAR T cells independent
of whether the tumor cells from which they were derived
expressed NTRK receptors. Our results demonstrate that non-
cell-mediated tumor-suppressive effects must be taken into
account for any CAR T cell-based therapy.
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